QUOTE AND NEWS
newratings.com  4 hrs ago  Comment 
Novartis data in The Lancet Oncology show LBH589 offers 4-month increase in median PFS for patients with multiple myeloma Novartis International AG / Novartis data in The Lancet Oncology show LBH589 offers 4-month increase in median PFS for...
newratings.com  Sep 17  Comment 
Novartis presents oncology research advances with new data on Zykadia(TM), Afinitor® and key pipeline compounds at ESMO 2014 Novartis International AG / Novartis presents oncology research advances with new data on Zykadia(TM), Afinitor® and...
FiercePharma  Sep 16  Comment 
So much for home field advantage. Switzerland plans to put the squeeze on drug prices, despite its corporate citizens Roche and Novartis. And the Basel-based companies are none too happy about the idea.
GenEng News  Sep 16  Comment 
The era of biosimilars has finally arrived. On July 24, 2014, over four years after the enactment of the Biologics Price Competition and Innovation Act, the FDA has approved for review the first biosimilar application, an application from Sandoz...
newratings.com  Sep 15  Comment 
BRUSSELS (dpa-AFX) - Swiss stocks saw little movement on Monday, weighed down by global economic jitters and renewed concerns about the situation in Ukraine. Health care majors Roche and Novartis continued to perform well, but Transocean and UBS...
Forbes  Sep 15  Comment 
Looking at units outstanding versus one week prior within the universe of ETFs covered at ETF Channel, the biggest outflow was seen in the Vanguard FTSE Europe ETF (VGK), where 6,899,648 units were destroyed, or a 2.6% decrease week over week. ...
newratings.com  Sep 13  Comment 
Novartis demonstrates leadership in ophthalmology with new products and over 40 abstracts at EURETINA Novartis International AG / Novartis demonstrates leadership in ophthalmology with new products and over 40 abstracts at EURETINA . Processed...
SeekingAlpha  Sep 12  Comment 
By Robert Honeywill: There was much excitement about Novartis' acute heart failure drug Serelaxin, when study results were first posted in late 2012. But in April this year, an FDA Committee unanimously rejected approval. In retrospect, there were...
StreetInsider.com  Sep 12  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Novartis+%28NVS%29+Affirms+High-Efficacy+of+Gilenya+in+Achieving+NEDA+in+RRMS+Patients/9827513.html for the full story.
newratings.com  Sep 12  Comment 
BASEL (dpa-AFX) - Novartis International AG (NVS) announced new data which confirmed the high efficacy of Gilenya, an oral disease-modifying therapy, in achieving 'no evidence of disease activity' or NEDA in patients...




 

Fuerralz? That's marvelously good to know.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki